2020-05-11 08:15
Uppsala, Sweden, May 11, 2020. The scientific journals British Journal of Cancer, a Nature journal, and Biomarkers in Medicine have published articles on DiviTum® results and TK activity as a biomarker for evaluating efficacy of CDK4/6 inhibitors. The...
2020-05-11 08:00
Uppsala, Sweden, May 11, 2020. Biovica, active in cancer diagnostics, hosts today its virtual capital market day at 14.00-16.00. The purpose is to provide an update on Biovica's market launch strategy and goals. Biovica is also providing a market share...
2020-05-06 10:25
Biovica, active in cancer diagnostics, will host a virtual Capital Markets Day on Monday 11 May from 14:00 to 16:00.
2020-04-29 11:38
Biovica, active in cancer diagnostics, will host a virtual Capital Markets Day on Monday 11 May from 14.00 to 16:00.
2020-04-08 08:00
Biovica and Mayo Clinic have entered into an agreement to study the clinical benefit of using DiviTum[®] as a blood-based test, monitoring the tumor response to therapy in patients with metastatic breast cancer.
2020-03-25 08:30
Uppsala, Sweden, March 25, 2020. Biovica, active in cancer diagnostics, today announced that Robert Dann is joining the organization as SVP Marketing and US Business and will be part of the management team. The appointment marks a significant milestone...
2020-03-12 08:30
Uppsala, Sweden, March 12, 2020. Biovica, active in cancer diagnostics, today announced that results from a study by researchers at Lund University have been published in the well renowned journal Scientific Reports, a journal from Nature. The results...
2020-03-12 08:00
Period: May-January 2019/2020
2020-03-10 22:03
Uppsala, Sweden, March 10, 2020. Biovica, active in cancer diagnostics, today announced that the company intends to submit an FDA application for market approval of DiviTum in the third quarter of 2020 and not as previously announced in mid-2020.
2020-01-16 08:00
Biovica, active in cancer diagnostics, today announced that the scientific journal Clinical Cancer Research has published data from the TREnd study, demonstrating the benefits of using DiviTum[®] when evaluating palbociclib treatment outcome in women...
>4,500
Numbers of patients in studies
28
Publications
32
Pharma Projects